Brazil acts to spur domestic production of key medicines

Brazil announced a major initiative Thursday to spur domestic production of medicines and equipment to combat diseases such as Alzheimers.

Alexandre Padilha said the plans call for major government investments in the field, public-private partnerships to produce drugs, and fast-tracking patents and registration of products crucial to .

He estimated that the measures would lead to savings of 354 million reais ($179 million) over five years, because the government currently imports most of the medicines involved and makes them available to the national health system.

"To produce here in Brazil means a saving for the government and the consumer," the Padilha said. "These products can lead to price reductions for the consumer."

He made the announcement at a meeting hosted by the Federation of Industries of the State of Sao Paolo.

He said the would extend seven billion reais ($3.5 billion) in credits to Brazilian firms involved in innovative health projects and pump another 1.3 billion reais ($651 million) into the infrastructure of public laboratories.

He said key regulatory bodies—the National Health Surveillance Agency ANVISA, the National Institute of Intellectual Property (INPI) and the Brazilian Association of Technical Norms (ABNT)—would sign agreements aimed at speeding up the process for obtaining patents and registering products.

add to favorites email to friend print save as pdf

Related Stories

Brazil moves to combat 'crack epidemic'

Dec 07, 2011

The Brazilian government on Wednesday launched a war on what it called a "crack epidemic", including medical treatment for addicts and a crackdown on trafficking, particularly in border areas.

Recommended for you

Using computers to design drugs

16 hours ago

Designing a new medicine is an expensive and time consuming business. Typically it takes around $2 billion and ten years for a new drug to move from its initial design in the lab, to the clinic. All the ...

Lilly psoriasis drug fares well in late-stage test

21 hours ago

Drugmaker Eli Lilly and Co. said its potential psoriasis treatment fared better than both a fake drug and a competitor's product during late-stage testing on patients with the most common form of the skin disease.

New US restrictions on painkiller to take effect

Aug 21, 2014

The federal government is finalizing new restrictions on hundreds of medicines containing hydrocodone, the highly addictive painkiller that has grown into the most widely prescribed drug in the U.S.

User comments